Drug intelligence / Profile preview

MAb 216

Development stage: Phase 1
Lead developer: Stanford University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MAb 216 is a naturally occurring human IgM monoclonal antibody derived from the VH4-34 (variable heavy chain) gene. It targets a linear B-cell lactosamine antigen (specifically a poly N-acetyllactosamine epitope) on the surface of B-lymphocytes. The antibody demonstrates direct cytotoxicity against B cells through a unique mechanism involving membrane disruption and pore formation. It has been studied primarily for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), both as a single agent and in combination with vincristine. Additional research has explored its potential in treating epithelial ovarian cancer (EOC).

Other names: Monoclonal Antibody 216

Beyond the preview

Go deeper on MAb 216.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb 216.

Explore the full profile